SpinalCyte Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018

HOUSTON – May 17, 2018 – SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using Human Dermal Fibroblasts (HDFs), today announced poster presentations highlighting a recent double-blind, placebo controlled human trial of CybroCell™ HDFs to treat degenerative disc disease along with Superior Immune Modulation for Arthritis and Treatment of Acute Liver Failure.

**Poster Presentation Details:**

**Title:** Efficacy of CybroCell™ Fibroblast Intradiscal Cellular Therapy for Disc Degenerative Disease  
**Number:** 776  
**Category:** Cell Therapies  
**Session:** Date & Time: Friday, May 18, 5:45P CDT  
**Location:** Stevens Salon C, D  
**Authors:** Pete O’Heeron¹, Jesus Perez², Javier Lopez², Amit N. Patel³, Courtney Bartlett³, Thomas E. Ichim¹

¹SpinalCyte LLC, Houston, TX, ²Institute for Regenerative Medicine, Baja, Mexico, ³University of Miami, Miami, FL

**Title:** Treatment of Acute Liver Failure Using CybroCell™ Universal Donor Fibroblast Therapy  
**Number:** 478  
**Category:** Cell Therapies  
**Session:** Date & Time: Thursday, May 17, 5:15P CDT  
**Location:** Stevens Salon C, D  
**Authors:** Thomas E. Ichim¹, Courtney Bartlett², Wei-Ping Min³, Amit N. Patel², Pete O’Heeron¹

¹SpinalCyte LLC, Houston, TX, ²University of Miami, Miami, FL, ³University of Western Ontario, London, ON, Canada

**Title:** Superior Immune Modulation and Anti-Arthritic Activity by CybroCell™ Compared to Bone Marrow Mesenchymal Stem Cells.  
**Number:** 231  
**Category:** Immunological Aspects of Gene and Cell Therapy  
**Session:** Date & Time: Thursday, May 17, 5:30P CDT  
**Location:** Stevens Salon C, D  
**Authors:** Thomas E. Ichim¹, Courtney Bartlett², Wei-Ping Min³, Amit N. Patel², Pete O’Heeron¹

¹SpinalCyte LLC, Houston, TX, ²University of Miami, Miami, FL, ³University of Western Ontario, London, ON, Canada
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a regenerative medicine company developing an innovative solution for spinal nucleus replacement using human dermal fibroblasts. Currently, SpinalCyte holds 25 U.S. and international issued patents and has filed for an additional 48 patents pending. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.

Investor Contact:
281.461.6211
info@spinalcyte.com

Media Contact:
Dan Keeney, APR
832.467.2904
dan@dpkpr.com